The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy-Reference-Cited by-同舟云学术

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

Published:2017-11 Issue:2 Volume:7 Page:e1390641
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ahmad Shamaila Munir¹,Martinenaite Evelina¹,Holmström Morten¹²^ORCID,Jørgensen Mia Aaboe¹,Met Özcan¹³⁴,Nastasi Claudia⁴,Klausen Uffe¹^ORCID,Donia Marco¹³,Pedersen Lars Møller⁵,Munksgaard Lars²,Ødum Niels⁴,Woetmann Anders⁴,Svane Inge Marie¹³,Andersen Mads Hald¹⁴

Affiliation:

1. Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark

2. Department of Hematology, Zealand University Hospital, DK-4000 Roskilde, Denmark

3. Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark

4. Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

5. Department of hematology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2017.1390641

Reference22 articles.

1. The targeting of immunosuppressive mechanisms in hematological malignancies

2. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

3. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors

4. PD-1 and Its Ligands in Tolerance and Immunity

5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics;PLOS ONE;2024-07-02

2. Programmed cell death-ligand 2: new insights in cancer;Frontiers in Immunology;2024-03-28

3. Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis;ESMO Gastrointestinal Oncology;2023-12

4. The role of PD-1 signaling in health and immune-related diseases;Frontiers in Immunology;2023-05-16

5. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy;Journal for ImmunoTherapy of Cancer;2023-03